GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Analysis AS (XSAT:GEAN) » Definitions » Scaled Net Operating Assets

Genetic Analysis AS (XSAT:GEAN) Scaled Net Operating Assets : 0.49 (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Genetic Analysis AS Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genetic Analysis AS's operating assets for the quarter that ended in Sep. 2024 was kr30.21 Mil. Genetic Analysis AS's operating liabilities for the quarter that ended in Sep. 2024 was kr9.37 Mil. Genetic Analysis AS's Total Assets for the quarter that ended in Jun. 2024 was kr42.28 Mil. Therefore, Genetic Analysis AS's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.49.


Genetic Analysis AS Scaled Net Operating Assets Historical Data

The historical data trend for Genetic Analysis AS's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Analysis AS Scaled Net Operating Assets Chart

Genetic Analysis AS Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
0.71 0.56 0.52 0.35 0.38

Genetic Analysis AS Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.56 0.37 0.54 0.49

Competitive Comparison of Genetic Analysis AS's Scaled Net Operating Assets

For the Diagnostics & Research subindustry, Genetic Analysis AS's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Analysis AS's Scaled Net Operating Assets Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Analysis AS's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Genetic Analysis AS's Scaled Net Operating Assets falls into.



Genetic Analysis AS Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Genetic Analysis AS's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(38.211-14.074)/64.425
=0.37

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=53.49 - 15.279
=38.211

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=21.492 - 5.448 - 1.97
=14.074

Genetic Analysis AS's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(30.214-9.369)/42.28
=0.49

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=41.616 - 11.402
=30.214

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=18.191 - 8.822 - 0
=9.369

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genetic Analysis AS Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Genetic Analysis AS's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Analysis AS Business Description

Traded in Other Exchanges
N/A
Address
Ulvenveien 80, Oslo, NOR, 0581
Genetic Analysis AS is a research-driven diagnostic company dedicated to delivering innovative diagnostic solutions to the growing human microbiota market. It is providing a CE-marked gut microbiota analysis for testing bacterial imbalance in IBS and IBD patients.

Genetic Analysis AS Headlines

No Headlines